Pharmafile Logo
Pharmafocus logo
Advanced Search

Bristol-Myers Squibb

Showing 15 posts of 146 posts found.

bmssyracuseny

BMS’ Opdivo+Yervoy combo fails in small cell lung cancer

November 27, 2018
Manufacturing and Production, Research and Development Bristol-Myers Squibb, Cancer, Yervoy, lung cancer, opdivo, pharma

Bristol-Myers Squibb has revealed that its combo comprising Opdivo (nivolumab) and Yervoy (ipilimumab) failed to meet its primary endpoint as …

News

FDA approves BMS’ multiple myeloma combo after it doubles progression-free survival

November 7, 2018
Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, Empliciti, FDA, US, multiple myeloma, pharma

The FDA has seen fit to approve Bristol-Myers Squibb’s Empliciti (elotuzumab) intravenous injection in combination with pomalidomide and dexamethasone for …

News

BMS’ Opdivo and Yervoy combination shows outstanding survival rate in cancer patients

October 22, 2018
Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, Yervoy, melanoma, opdivo

American pharma firm Bristol-Myers Squibb have announced that more than 53% of patients with advanced melanoma, who were treated with …

News

BMS’ Opdivo fails to improve overall survival in small-cell lung cancer

October 15, 2018
Research and Development, Sales and Marketing BMS< Opdivo, Bristol-Myers Squibb, Cancer, lung cancer, pharma

Bristol-Myers Squibb’s Opdivo (nivolumab) failed to deliver on its primary endpoint in a Phase 3 study in small-cell lung cancer, …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week

September 14, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bristol-Myers Squibb, FDA, NICE, Novo Nordisk, Spinraza, brexit, bristol myers squibb, top 10

With the Pharmafocus team having avoided hurricane Florence and finally arriving back in the UK just last night, after stopping …

News

BMS’ investigational psoriasis drug hits primary endpoint in skin clearance at Phase 2

September 12, 2018
Research and Development BMS, BMS-986165, Bristol-Myers Squibb, pharma, psoriasis

Bristol-Myers Squibb has unveiled new Phase 2 data for its investigational oral, selective tyrosine kinase 2 (TYK2) inhibitor, known as …

News

Bristol-Myers Squibb appoints Christopher Boerner as new Executive Vice President and Chief Commercial Officer

August 30, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, bristol myers squibb, cco, chief commercial officer, christopher boerner, executive vice president, murdo gordon

Bristol Myers Squibb has announced that Dr Christopher Boerner will take over from Murdo Gordon as executive Vice President and …

Appointment
Image Credit: Bristol-Myers Squibb

FDA approves Bristol Myers Squibb’s Opdivo in small-cell lung cancer

August 20, 2018
Sales and Marketing Bristol-Myers Squibb, FDA, approval, bristol myers squibb, lung cancer, opdivo

The FDA has approved Bristol Myers Squibb’s Opdivo (nivolumab) for patients with metastatic small-cell lung cancer (SCLC), as the first …

News
murdo_gordon-bio

Bristol Myers Squibb announces departure of Chief Commercial Officer

July 24, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bristol-Myers Squibb, bristol myers squibb, commerical executive, marketing, sales

Bristol Myers Squibb has announced that Executive Vice President and Chief Commercial Officer, Murdo Gordon, who has been with the …

Appointment
opdivo_1_1

NICE turns down BMS’ blockbuster Opdivo for urothelial carcinoma

July 5, 2018
Sales and Marketing BMS, Bristol-Myers Squibb, NICE, opdivo, pharma, urothelial carcinoma

Just in time for the NHS’ 70th birthday, UK watchdog NICE has announced that it has taken the decision to …

News
pharmafocus_july-august_2018_cover

The July/August issue of Pharmafocus is now live!

July 4, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bristol-Myers Squibb, Elizabeth Holmes, NHS, Sanofi, Theranos, UK, ambien, manufacturing compliance, opdivo, patient recruitment, patient retention, pharma

The new July/August edition of Pharmafocus is now available to read online.

News

Cadila scores FDA approval for BMS and Alvogen generics

July 3, 2018
Manufacturing and Production, Sales and Marketing Adolat, Alvogen, Bristol-Myers Squibb, Cadila, FDA, Questran, generics, pharma

Cadila Healthcare has announced that it has gained FDA final approval to market nifedipine ER tablets in the strengths of …

News
opdivo_1_1

BMS’ Opdivo becomes first immuno-oncology agent available in China

June 18, 2018
Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, China, NSCLC, lung cancer, oncology, opdivo, pharma

Bristol-Myers Squibb’s flagship immunotherapy Opdivo (nivolumab) has broken ground to become the first and only PD-1 inhibitor to be made …

News
nektar-therapeutics

“Underwhelming” drug data devastates Nektar, shares fall by 42%

June 5, 2018
Manufacturing and Production, Research and Development ASCO, BMS, Bristol-Myers Squibb, Cancer, Nektar, bristol myers-squibb, pharma

Nektar Therapeutics has seen its share price devastated after revealing disappointing trial data for its candidate NKTR-214 in combination with …

News
shutterstock_159488225

New cancer clinical trial model promises to cut costs and development time

May 15, 2018
Manufacturing and Production, Research and Development BMS, Bristol-Myers Squibb, Cancer, MD AndersonCancer Center, clinical trials, pharma

Researchers from the University of Texas MD Anderson Cancer Center have been developing and testing a new model for the …

News

Latest content

FDA accepts new drug application for Orexo’s opioid overdose medication

November 28, 2023

Arcturus Therapeutics gains FDA ODD for cystic fibrosis treatment

November 28, 2023

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

November 27, 2023

GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment

November 27, 2023

Alladapt Immunotherapeutics gains FDA Fast Track Designation for ADP101 as food allergy treatment

November 24, 2023